Download PDF
Thromb Haemost 1994; 72(02): 328-329
DOI: 10.1055/s-0038-1648865
Letter to the Editor
Schattauer GmbH Stuttgart

Cost Effectiveness and Ease of Administration of Low Molecular Weight Heparin in Deep Vein Thrombosis

C P Teo
Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore
,
H L Lim
Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore
,
Y K Kueh
Division of Haematology/Oncology, Department of Medicine, National University Hospital, Singapore
› Author Affiliations
Further Information

Publication History

Received 03 March 1994

Accepted after revision 22 April 1994

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin fragmin: results of a doubleblind randomized study. Circulation 1989; 80: 935-940
    CrossrefPubMedGoogle Scholar
  • 2 Simoneau G. for the TVPENOX Group Study. Subcutanous fixed dose of enoxaparine (E) versus intravenous adjusted dose of unfractionated heparin(UH) in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1991: 65-754
    PubMedGoogle Scholar
  • 3 Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractioned heparin in the treatmentof deep vein thrombosis: a collaborative European multicentre study. Thromb Haemost 1991; 65: 1058-1063
    PubMedGoogle Scholar
  • 4 Prandoni P, Lensing AWA, Buller HP, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Ten Cate JW. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximaldeep-vein thrombosis. Lancet 1992; 339: 441-445
    CrossrefPubMedGoogle Scholar
  • 5 Levesque H, Vasse D, Legallicier B, Callieux N, Moore N, Borg JY, Cour-tois H. Letter to Lancet 1993; 341: 824-825
    PubMed